SRPT vs. WULF

In the year-to-date period, SRPT achieves a -68.80% return, which is significantly lower than WULF's -29.33% return. Over the past 10 years, SRPT has outperformed WULF with an annualized return of 3.76%, while WULF has yielded a comparatively lower -11.21% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and TeraWulf Inc. (WULF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SRPT Sharpe Ratio is -1.01, which is lower than the WULF Sharpe Ratio of 0.87. The chart below compares the historical Sharpe Ratios of SRPT and WULF, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SRPT nor WULF has paid dividends to shareholders.

The maximum SRPT drawdown since its inception was -98.17%, roughly equal to the maximum WULF drawdown of -98.50%. Use the drawdown chart below to compare losses from any high point for SRPT and WULF. For additional features, visit the drawdowns tool.

Sarepta Therapeutics, Inc. (SRPT) has a higher volatility of 40.97% compared to TeraWulf Inc. (WULF) at 35.37%. This indicates that SRPT's price experiences larger fluctuations and is considered to be riskier than WULF based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and TeraWulf Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.